Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis

Therapeutics and Clinical Risk Management

Volumn 4, Issue 5, 2008, Pages 843-853

  McGregor, Jessina C ^a   Allen, George P ^a   Bearden, David T ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

Levofloxacin; Pyelonephritis; Urinary tract infection

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; CIPROFLOXACIN; COTRIMOXAZOLE; DNA TOPOISOMERASE (ATP HYDROLYSING); GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ABNORMAL LABORATORY RESULT; ACUTE PYELONEPHRITIS; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; COMPLICATED URINARY TRACT INFECTION; CONVULSION; CYSTITIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSPEPSIA; DYSPNEA; ERADICATION THERAPY; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PHOTOSENSITIVITY; POINT MUTATION; PROSTATITIS; QT PROLONGATION; RESPIRATORY TRACT INFECTION; REVIEW; SINGLE DRUG DOSE; TENDON RUPTURE; URINARY TRACT INFECTION; VAGINITIS;

EID: 56749125023     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Anderson RU. 1996. Treatment of complicated and uncomplicated urinary tract infections. Antibiotic therapy in urology. S. G. Mulholland, Philadelphia: Lippincott-Raven Publishers. p 23-37.
2. Anderson VR, Perry CM. 2008. Levofloxacin:a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs, 68:535-65.
3. Baudry PJ, Nichol K, DeCorby M, et al. 2008. Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units. Antimicrob Agents Chemother, 52:1846-9.
4. Bundrick W, Heron SP, Ray P, et al. 2003. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology, 62:537-41.
5. Chang TM, Lu PL, Li HH, et al. 2007. Characterization of fluoroquinolone resistance mechanisms and their correlation with the degree of resistance to clinically used fluoroquinolones among Escherichia coli isolates. J Chemother, 19:488-94.
6. Chenia HY, Pillay B, Pillay D. 2006. Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens. J Antimicrob Chemother, 58:1274-8.
7. Cox CE, Holloway WJ, Geckler RW 1995. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients. Clin Infect Dis, 21:86-92.
8. Czaja CA, Scholes D, Hooton TM, et al. 2007. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis, 45:273-80.
9. David RD, DeBlieux PM, Press R. 2005. Rational antibiotic treatment of outpatient genitourinary infections in a changing environment. Am J Med, 118(Suppl 7A): 7S-13S.
10. Davis R, Bryson HM. 1994. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs, 47:677-700.
11. Drusano GL, Preston SL, Van Guilder M, et al. 2000. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother, 44:2046-51.
12. Fish DN, Chow AT. 1997. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet, 32:101-19.
13. Foxman B. 2002. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med, 113(Suppl 1A):5S-13S.
14. Grabe M, Bishop MC, Bjerklund-Johansen TE, et al. 2008. Guidelines on the management of urinary and male genital tract infections, European Association of Urology.
15. Gupta K, Hooton TM, Roberts PL, et al. 2007. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med, 167:2207-12.
16. Gupta K, Hooton TM, Stamm WE. 2005. Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis. J Antimicrob Chemother, 56:243-6.
17. Gupta K, Hooton TM, Wobbe CL, et al. 1999a. The prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in young women. Int J Antimicrob Agents, 11:305-8.
18. Gupta K, Scholes D, Stamm WE. 1999b. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA, 281:736-8.
19. Hooton TM, Stamm WE. 1991. Management of acute uncomplicated urinary tract infection in adults. Med Clin North Am, 75:339-57.
20. Kallen AJ, Welch HG, Sirovich BE. 2006. Current antibiotic therapy or isolated urinary tract infections in women. Arch Intern Med, 166:635-9.
21. Khashab MM, Xiang J, Kahn JB. 2006. Comparison of the adverse event profiles of levofloxacin 500mg and 750mg in clinical trials for the treatment of respiratory infections. Curr Med Res Opin, 22:1997-2006.
22. Klausner, HA, Brown P, Peterson J, et al. 2007. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Curr Med Res Opin, 23:2637-45.
23. Klimberg IW, Cox CE 2nd, Fowler CL, et al. 1998. A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection. Urology, 51:610-5.
24. Komp Lindgren P, Karlsson A, Hughes D. 2003. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother, 47:3222-32.
25. Langtry HD, Lamb HM. 1998. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Drugs, 56:487-515.
26. Lautenbach E, Strom BL, Bilker WB. 2001. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis, 33:1288-94.
27. Le TP, Miller LG. 2001. Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis. Clin Infect Dis, 33:615-21.
28. Matsumoto T, Takahashi K, Manabe N, et al. 2001. Urinary tract infection in neurogenic bladder. Int J Antimicrob Agents, 17:293-7.
29. Mazzulli T. 2001. Antimicrobial resistance trends in common urinary pathogens. Can J Urol, 8(Suppl 1):2-5.
30. McCue JD. 1999. UTIs in at-risk patients: are they 'complicated'? Infect Med, 16:533-40.
31. Mehlhorn AJ, Brown DA. 2007. Safety concerns with fluoroquinolones. Ann Pharmacother, 41:1859-66.
32. Melekos MD, Skoutelis A, Chryssanthopoulos C, et al. 1991. A comparative study on aztreonam, ceftazidime and amikacin in the treatment of complicated urinary tract infections. J Chemother, 3:376-82.
33. Morrissey I, Hoshino K, Sato K, et al. 1996. Mechanism of differential activities of ofloxacin enantiomers. Antimicrob Agents Chemother, 40:1775-84.
34. Muratani T, Matsumoto T. 2006. Urinary tract infection caused by fluoroquinolone- and cephem-resistant Enterobacteriaceae. Int J Antimicrob Agents, 28(Suppl 1):S10-3.
35. Naber KG. 1999. Experience with the new guidelines on evaluation of new anti-infective drugs for the treatment of urinary tract infections. Int J Antimicrob Agents, 11:189-96; discussion 213-6.
36. Naber KG. 2001. Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int J Antimicrob Agents, 17:331-41.
37. Naber KG, Roscher K, Botto H, et al. 2008. Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis. Int J Antimicrob Agents, 32:145-53.
38. Neal DE Jr. 2008. Complicated urinary tract infections. Urol Clin North Am, 35:13-22.
39. Nicolle LE. 1997. A practical guide to the management of complicated urinary tract infection. Drugs, 53:583-92.
40. Nowe P. 1994. Piperacillin/tazobactam in complicated urinary tract infections. Intensive Care Med, 20(Suppl 3): S39-42.
41. Peng MY. 1999. Randomized, double-blind, comparative study of levofloxacin and ofloxacin in the treatment of complicated urinary tract infections. J Microbiol Immunol Infect, 32:33-9.
42. Peterson J, Kaul S, Khashab M, et al. 2008. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology, 71:17-22.
43. Richard GA, Childs SJ, Fowler CL, et al. 1998a. Safety and efficacy of levofloxacin versus ciprofloxacin in complicated urinary tract infections in adults. Pharm Ther, 23:534-40.
44. Richard GA, Klimberg IN, Fowler CL, et al. 1998b. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology, 52:51-5.
45. Richard GA, Mathew CP, Kirstein JM, et al. 2002. Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. Urology, 59:334-9.
46. Ronald AR, Harding GK. 1997. Complicated urinary tract infections. Infect Dis Clin North Am, 11:583-92.
47. Rubin RH, Shapiro ED, Andriole VT, et al. 1992. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis, 15(Suppl 1):S216-27.
48. Sobel JD, Kaye D. 2005. Urinary tract infections. In: Mandell GL, Douglas RG, Bennett JE, et al. (eds). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. New York: Elsevier/ Churchill Livingstone. 1:875-905.
49. US Department of Health and Human Services, Food and Drug Administration and Center for Drug Evaluation and Research (CDER). 1998. Guidance for Industry. Complicated urinary tract infections and pyelonephritis-developing antimicrobial drugs for treatment. Clin-Anti. Rockville, MD, Drug Information Branch. Division of Communications Management.
50. Warren JW. 2001. Practice guidelines for the treatment of uncomplicated cystitis. Curr Urol Rep, 2:326-9.
51. Warren JW, Abrutyn E, Hebel JR, et al. 1999. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis, 29:745-58.
52. Wells WG, Woods GL, Jiang Q, et al. 2004. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother, 53(Suppl 2):ii67-74.
53. Xiong Z, Zhu D, Wang F, et al. 2002. Investigation of extended-spectrum beta-lactamase in Klebsiellae pneumoniae and Escherichia coli from China. Diagn Microbiol Infect Dis, 44:195-200.
54. Zhanel GG, Hisanaga TL, Laing NM, et al. 2006. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents, 27:468-75.